Saukkonen K, Abdillahi H, Poolman J T, Leinonen M
National Public Health Institute, Helsinki, Finland.
Microb Pathog. 1987 Oct;3(4):261-7. doi: 10.1016/0882-4010(87)90059-3.
The protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 was tested in an infant rat infection model. Four monoclonal antibodies to class 1 protein had bactericidal titres exceeding 20,000 and they protected infant rats completely against bacterial challenge with meningococci carrying the same class 1 protein, P1.16. One monoclonal antibody to class 3 protein was highly bactericidal (titer greater than 20,000), whereas two others had no bactericidal activity. All these antibodies gave some protection from infection, resulting in mortalities varying from 66 to 83% as compared to 100% in control rats who had received either unrelated monoclonal antibody or saline. These results strongly speak for class 1 outer membrane protein as a vaccine candidate for meningococcus group B.
在幼鼠感染模型中测试了针对B群脑膜炎奈瑟菌1类和3类外膜蛋白的单克隆抗体的保护效力。四种针对1类蛋白的单克隆抗体的杀菌效价超过20,000,它们能完全保护幼鼠免受携带相同1类蛋白P1.16的脑膜炎球菌的细菌攻击。一种针对3类蛋白的单克隆抗体具有高杀菌活性(效价大于20,000),而另外两种则没有杀菌活性。所有这些抗体都提供了一定程度的感染保护,与接受无关单克隆抗体或生理盐水的对照大鼠100%的死亡率相比,死亡率在66%至83%之间。这些结果有力地表明1类外膜蛋白是B群脑膜炎球菌的候选疫苗。